Market access risk in cardiology

Cardiology is the field where the cheapest medicines on earth set the price of the newest. Statins, blood-pressure tablets and the older anticoagulants cost pennies, work well, and are taken by tens of millions of people — so every new cardiovascular drug is judged against them, on populations so large that even a modest price becomes a national budget line. At the same time the field now has its own rare corner: inherited cholesterol disorders, heart-muscle disease and amyloid heart disease, where a few thousand patients meet prices once reserved for cancer. This page brings together MARA's independent assessments of reimbursement risk across both ends of the field.

What payers ask in cardiology

Does it prevent events, or move a number? Most cardiovascular approvals rest on a laboratory value — cholesterol, blood pressure, triglycerides — long before anyone knows whether fewer heart attacks and strokes follow. Payers have learned to separate the two. A drug that only moves the number is reimbursed narrowly, or not at all, until the outcomes trial reads out.

How much better than a generic, and for whom? The comparator in cardiology is usually a tablet that costs almost nothing. Payers ask what the new drug adds on top of it, and then draw the reimbursed group as tightly as the evidence allows — the highest-risk patients, those who cannot tolerate the standard, those already on maximum therapy.

What does a lifetime on treatment cost the system? Cardiovascular drugs are taken for decades by very large populations. Payers multiply price by years by patients before they look at anything else, and the answer decides whether a drug is covered broadly, covered with prior authorisation, or placed behind cheaper steps.

Is the convenience worth paying for? Twice-yearly injections, once-daily tablets replacing injections, drugs that need no monitoring: the field increasingly sells adherence. Payers accept that patients take convenient medicines more faithfully — and still ask for proof that the convenience changes outcomes, not only prescriptions.

The MARA record in cardiology

Cardiology holds nearly thirty dated assessments in the MARA catalogue: cholesterol and triglyceride lowering from oral tablets to twice-yearly injections, resistant hypertension, anticoagulation and stroke prevention, heart failure, hypertrophic cardiomyopathy and amyloid heart disease. Each report answers the same payer questions, carries its "as of" date, and stays on the record — when the evidence moves, a newer vintage replaces the older one visibly, never silently. Assessments are produced on MARA's own initiative for awareness; the current MARA Rating for any drug is available on request.

Current assessments (24)

Earlier assessments (each replaced by a newer version)

Selected commentary

For how a MARA Rating is built, see the methodology and what a MARA Rating is. To request the current rating for any drug in this area, use the contact form.